Also addition of solution of glutathione (GSH) transferase in the reaction mixture caused a marked increase in the rate of reaction compared to the non-enzymatic, showing monobromobimane was a substrate for this enzyme ( Figure 1 )
The same study also showed more people on Tirzepatide hitting large weight-loss milestones ( 15 %, 20 %, even 25 % of body weight) compared with Semaglutide
The most common side effects are injection-site soreness (41%, lasting 24-36 hours), mild nausea (12-15%, lasting 4-8 hours), and skin flushing (8-10%, lasting 10-30 minutes)
Thats why smart users inject it subcutaneously
It co-occurs with moderate IR and metabolic dysfunction
FDA Disclaimer: Medications referenced in this article, such as GLP-1 receptor agonists (semaglutide, tirzepatide), are FDA-approved for weight management and diabetes treatment but require a valid prescription